AVPR2 and autosomal dominant polycystic kidney disease: The use of V2R antagonists such as tolvaptan, which inhibits V2R signaling reducing cAMP levels in renal collecting duct cells (Figure 2A), has proven to be a successful strategy in ADPKD.